Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome (PLDS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04141969
Recruitment Status : Completed
First Posted : October 28, 2019
Last Update Posted : April 12, 2021
Information provided by (Responsible Party):
Optimal Health Research

Brief Summary:
This study will determine the effectiveness of a nutraceutical in treating the lingering effects of Lyme Disease after antibiotic treatment.

Condition or disease Intervention/treatment Phase
Post-Lyme Disease Syndrome (PLDS) Dietary Supplement: RLP Other: Placebo Phase 2 Phase 3

Detailed Description:
A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome will be evaluated during a double blind, placebo controlled study. This study is an expansion of RLP042019 NCT04078841 Treating Post-Lyme Disease Syndrome With Acetogenins

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome
Actual Study Start Date : November 29, 2019
Actual Primary Completion Date : December 31, 2020
Actual Study Completion Date : March 28, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lyme Disease

Arm Intervention/treatment
Active Comparator: RLP
Dietary Supplement: RLP
RLP nutraceutical

Placebo Comparator: Inert
Inert brown powder to look similar to RLP
Other: Placebo
Inert brown powder

No Intervention: Control
Not given RLP or the placebo

Primary Outcome Measures :
  1. PROMIS Global-10 [ Time Frame: 6 months ]
    PROMIS Global-10; Self reported level changes as measured by the Patient-Reported Outcomes Measurement Information System Global-10 .

  2. IHT Blood Test Assessment [ Time Frame: 6 months ]
    Outcome measure of "positive" or "negative" for antibodies; IgG P93 Ab. IgG P66 Ab. IgG P58 Ab. IgG P45 Ab. IgG P41 Ab. IgG P39 Ab. IgG P30 Ab. IgG P28 Ab. IgG P23 Ab. IgG P18 Ab.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 75 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. A positive two-test methodology using a sensitive enzyme immunoassay (EIA) or immunofluorescence assay as a first test, followed by a western immunoblot assay for specimens yielding positive or equivocal results for Lyme Disease that has been treated with antibiotics but the symptoms persist post treatment.
  2. Must be able to swallow a mixed powder drink.

Exclusion Criteria:

1 .Non Positive Western Blot test.

2. Positive Western Blot test where the individual has not been treated with antibiotics.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04141969

Layout table for location information
United States, Utah
Optimal Health Research
Salt Lake City, Utah, United States, 84117
Sponsors and Collaborators
Optimal Health Research
Layout table for investigator information
Principal Investigator: Dr Osguthorpe, ND Optimal Health Research
Layout table for additonal information
Responsible Party: Optimal Health Research Identifier: NCT04141969    
Other Study ID Numbers: RLP10242019
First Posted: October 28, 2019    Key Record Dates
Last Update Posted: April 12, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Optimal Health Research:
Additional relevant MeSH terms:
Layout table for MeSH terms
Lyme Disease
Post-Lyme Disease Syndrome
Pathologic Processes
Gram-Negative Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses
Borrelia Infections
Spirochaetales Infections
Tick-Borne Diseases
Vector Borne Diseases